Pieris Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
Pieris Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company's pipeline includes PRS-080, a multi-receptor antagonist, which is in Phase II clinical trial for the treatment of dry eye disease, and PRS-094, a transmembrane domain protein receptor antagonist for the treatment of melanoma, colorectal cancer, and multiple myeloma. Pieris Pharmaceuticals was founded in 2009 and is based in Lexington, Massachusetts.
Latest articles
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
Ticker symbol
PIRS
Country
🇺🇸 United States